Evolus, Inc. reported a net loss of $51.6 million for the fiscal year ending December 31, 2025, a slight increase from the $50.4 million loss recorded in 2024. The company's total net revenues rose to $297.2 million, reflecting an 11.6% increase from $266.3 million in the previous year. This growth was primarily driven by the successful launch of Evolysse™, a collection of injectable hyaluronic acid gels, and increased sales of Jeuveau®, its flagship botulinum toxin product. However, the gross profit margin decreased to 66.3% from 68.5% in 2024, attributed to rising costs associated with the increased volume of products sold.
In terms of operational developments, Evolus launched Evolysse™ Form and Evolysse™ Smooth in the United States in April 2025, with plans to introduce the full Evolysse™ product line in Europe by the second quarter of 2026. The company also anticipates regulatory approval for additional Evolysse™ products, Sculpt and Lips, in the U.S. in 2026 and 2027, respectively. As of December 31, 2025, Evolus had 334 employees, all full-time, with a significant focus on expanding its sales and marketing capabilities to support its product launches.
Evolus has faced challenges related to its financial structure, including a significant accumulated deficit of $661 million as of the end of 2025. The company has entered into various financing agreements, including a $250 million senior secured term loan with Pharmakon and a $30 million revolving credit facility with Eclipse Business Capital, to bolster its liquidity. Despite these efforts, the company reported cash and cash equivalents of $53.8 million at year-end, down from $87 million in 2024, indicating a need for ongoing capital management.
Looking ahead, Evolus remains focused on expanding its market presence in the cash-pay aesthetic sector, which is sensitive to consumer discretionary spending and economic conditions. The company is aware of the potential impact of macroeconomic factors, including inflation and tariffs, on consumer sentiment and spending behavior. Evolus plans to continue investing in marketing and promotional strategies to drive product adoption and maintain competitive positioning in a rapidly evolving market. The company’s future performance will depend on its ability to navigate these challenges while achieving regulatory milestones and expanding its product offerings.
About Evolus, Inc.
Evolus, Inc. is a global aesthetic company specializing in non-reimbursed, consumer-pay medical products. Its core offerings include injectable neurotoxins like Jeuveau and hyaluronic acid gels such as Evolysse. Serving aesthetic practitioners and consumers worldwide, the company emphasizes high-quality, minimally invasive treatments, digital marketing, and strategic licensing to drive growth in the expanding medical aesthetics market.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.